Literature DB >> 3281747

The contribution of medicine to the primary treatment of breast cancer.

G Bonadonna1, P Valagussa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3281747

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  8 in total

1.  Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay.

Authors:  C M Kurbacher; I A Cree; U Brenne; H W Bruckner; J A Kurbacher; P Mallmann; P E Andreotti; D Krebs
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 2.  Axillary surgery in breast cancer patients.

Authors:  A Millet; C A Fuster; A Lluch; F Dirbas
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.405

3.  Prognostic value of epidermal growth factor receptor in node-positive breast cancer.

Authors:  M Grimaux; S Romain; Y Remvikos; P M Martin; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

4.  Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC).

Authors:  Katalin Boér; István Láng; Eva Juhos; Tamás Pintér; János Szántó
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

5.  Host heterogeneity in female breast cancer: possible significance for pathophysiology, therapy, and prevention.

Authors:  P Cohen
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

6.  Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy.

Authors:  P Valagussa; M Zambetti; G Bonadonna; R Zucali; G Mezzanotte; U Veronesi
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

7.  Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma.

Authors:  G Gasparini; S Dal Fior; F Pozza; P Bevilacqua
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

8.  Fluorouracil catabolism in the combination treatment of cyclophosphamide, methotrexate and fluorouracil.

Authors:  E A De Bruijn; S A Van der Heyden; E E Gheuens; R A Maes
Journal:  Jpn J Cancer Res       Date:  1992-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.